Cadrenal Therapeutics, Inc.
NASDAQ · us_market
No AI insight generated yet for this ticker.
Cadrenal Therapeutics, Inc. operates as a late-stage biopharmaceutical company that develops novel therapies for life-threatening immune and thrombotic conditions. The company is developing Tecarfarin, an oral vitamin K antagonist that is in Phase 3 clinical trial designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, and atrial fibrillation; CAD-1005, a first-in-class 12-LOX inhibitor for the treatment of heparin-induced thrombocytopenia, a deadly immune-mediated thrombotic disorder that has completed Phase 2 clinical trial; and Frunexian, a parenteral clinical-stage factor XIa inhibitor designed for use in acute hospital settings that has completed Phase 1 clinical trial. It has a collaboration agreement with Abbott Global Enterprises Limited to evaluate the efficacy and safety of Tecarfarin in patients with a left-ventricular assist device. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-05-07 | -1.57 | -1.04 | +33.97% |
| 2026-03-31 | -1.21 | -1.41 | -16.53% |
| 2025-11-10 | -1.55 | -1.31 | +15.48% |
| 2025-08-11 | -1.77 | -1.87 | -5.35% |
| 2025-05-08 | -2.15 | -2.09 | +2.79% |
| 2025-03-13 | -1.86 | -8.73 | -368.10% |
| 2024-11-07 | -1.80 | -2.18 | -21.11% |
| 2024-08-07 | -1.80 | -2.25 | -25.00% |
| 2024-05-09 | -1.35 | -1.50 | -11.11% |
| 2024-03-11 | -1.35 | -1.87 | -38.89% |
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| CVKD | -21.89% | -38.99% | -26.84% | -62.79% |
| XLV | +2.97% | -4.64% | -3.44% | +12.69% |
| Alpha (stock − sector) | -24.86% | -34.35% | -23.40% | -75.48% |